Impaired negative regulation of homeostatically proliferating T cells

Blood

Volumn 113, Issue 3, 2009, Pages 622-625

  Shvets, Anna ^a   Chakrabarti, Rabindranath ^a   Gonzalez Quintial, Rosana ^b   Baccala, Roberto ^b   Theofilopoulos, Argyrios N ^b   Prud'homme, Gérald J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; PD 1 LIGAND 1; PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AUTOANTIGEN; B7 H4 PROTEIN, MOUSE; B7-H4 PROTEIN, MOUSE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; PD 1 ANTIGEN, MOUSE; PD-1 ANTIGEN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; LYMPHOCYTOPENIA; METABOLISM;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; AUTOANTIGENS; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; LYMPHOPENIA; MICE; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 60249103438     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-139964     Document Type: Article

References (25)

1. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;10:185-192.
2. Baccala R, Gonzalez-Quintial R, Dummer W, et al. Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives. Springer Semin Immunopathol. 2005; 27:75-85.
3. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol. 2007;19:318-330.
4. Neujahr DC, Chen C, Huang X, et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol. 2006; 176:4632-4639.
5. Borrello I, Sotomayor EM, Rattis FM, et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)- producing tumor vaccines. Blood. 2000;95:3011- 3019.
6. Hu HM, Poehlein CH, Urba WJ, et al. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002;62: 3914-3919.
7. Asavaroengchai W, Kotera Y, Mule' JJ. Tumor lysate- pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A. 2002; 99:931-936.
8. + T cell anergy and promotes tumor rejection. J Immunol. 2006;177:4521-4529.
9. Wrzesinski C, Paulos CM, Gattinoni L, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007;17:492-501.
10. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004;101(suppl 2): 14639-14645.
11. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.
12. Ge Q, Hu H, Eisen HN, et al. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Natl Acad Sci U S A. 2002;99:2989-2994.
13. Cho BK, Rao VP, Ge Q, et al. Homeostasisstimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med. 2000;192:549-556.
14. Li CR, Santoso S, Lo DD, et al. Quantitative analysis of T cell homeostatic proliferation. Cell Immunol. 2007;250:40-54.
15. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307-314.
16. +T cells. Nat Immunol. 2006;7:475-481.
17. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203:2223-2227.
18. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007;87:1077-1091.
19. Pyzik M, Piccirillo CA. The TGF-beta1/Foxp3 regulatory axis in immune self-tolerance: implications for health and disease. Inflamm Allergy Drug Targets. 2006;5:167-177.
20. + regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A. 2007;104:8959-8964.
21. Kline J, Brown IE, Zha YY, et al. TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of b16 melanoma. Clin Cancer Res. 2008;14:3156-3167.
22. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
23. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30: 251-260.
24. Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferongamma receptor/IgG1 fusion protein. Gene Ther. 1999;6:771-777.
25. Chakrabarti R, Zhou ZF, Chang Y, et al. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity. Vaccine. 2005;23:4553-4564.